Unimac Pharmaceutical Private Limited
About Unimac Pharmaceutical Private Limited
Data last updated:
Unimac Pharmaceutical Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 02 August 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2018PTC337110. Its GSTIN is 07AACCU2822K1ZB (Delhi).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Sunil Chugh and Deepak Batra.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at B – 23 F/F Kh.No.32/11/1 Panjabi Basti Nangloi, New Delhi, Delhi, India – 110041.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.71 Cr, a growth of 28% compared to the previous year. For the same year it recorded a net profit of ₹8.92 Lakh (net margin 3.3%) and EBITDA of ₹17.98 Lakh (EBITDA margin 6.6%). Revenue has grown at a compounded annual rate (CAGR) of 47% over three years and 33% over five years.
Court records list 2 cases involving the company, including 2 filed against it.
Company details
Contact details
Unimac Pharmaceutical Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressB – 23 F/F Kh.No.32/11/1 Panjabi Basti Nangloi, New Delhi, Delhi, India – 110041
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Unimac Pharmaceutical Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Unimac Pharmaceutical is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Unimac Pharmaceutical Private Limited, buy the company report.
Financials of Unimac Pharmaceutical Private Limited
FY 2024 filings availableUnimac Pharmaceutical Private Limited reported revenue of ₹2.71 Cr (up 28% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 33% over five years, including 28% growth in the latest year. EBITDA rose 16% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹17.98 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.92 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.6% | ||||
| Net Profit Margin | 3.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Unimac Pharmaceutical Private Limited, buy the company report.
Board of directors of Unimac Pharmaceutical Private Limited
Unimac Pharmaceutical has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sunil Chugh Also directs: Amblish Healthcare Private Limited | Director | 02 Aug 2018 | 8 Years 2 Months | Current |
| Deepak Batra Also directs: Amblish Healthcare Private Limited | Director | 02 Aug 2018 | 8 Years 2 Months | Current |
Peer comparison
Unimac Pharmaceutical Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Tetramed Biotek Private Limited | ₹2.73 Cr (FY 2022) | 4.0% | Pune, Maharashtra, India | |||
| Sanket Pharmaceuticals Pvt Ltd | ₹2.71 Cr (FY 2025) | -8.0% | Mumbai, Maharashtra, India | |||
| Umar Medicare Private Limited | ₹2.71 Cr (FY 2022) | 269.0% | Delhi, India | |||
| Unimac Pharmaceutical Private Limitedthis company | ₹2.71 Cr (FY 2025) | ₹8.92 Lakh | 3.3% | 28.0% | New Delhi, Delhi, India | |
| Medtabs Pharma Private Limited | ₹2.71 Cr (FY 2024) | 40.0% | Satara, Maharashtra, India | |||
| Proficon Medisol Private Limited | ₹2.71 Cr (FY 2025) | -45.0% | Delhi, India | |||
| Balaark Pharmaceuticals Private Limited | ₹2.7 Cr (FY 2025) | 5.0% | Pune, Maharashtra, India |
To see the full peer comparison of Unimac Pharmaceutical Private Limited, buy the company report.
Auditor
Unimac Pharmaceutical Private Limited is audited by DAM & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DAM & Associates | FY 2023 | 033673N |
Shareholding
The shareholding of Unimac Pharmaceutical Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Unimac Pharmaceutical Private Limited, buy the company report.
Legal cases
Unimac Pharmaceutical Private Limited has 2 court cases on record: 2 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 2 | 0 |
Cases on record (1 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South West, Delhi | Civil suit | Filed against the company by State | Disposed |
To see the full case history of Unimac Pharmaceutical Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Unimac Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Unimac Pharmaceutical has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AACCU2822K1ZB | Delhi | Active | 25 Oct 2018 |
To see the full GST registrations and return filing status of Unimac Pharmaceutical Private Limited, buy the company report.
Recent activity
Unimac Pharmaceutical Private Limited has 2 board changes on record since 2018: 2 appointments. The latest: Deepak Batra was appointed as Director on 02 Aug 2018.
Frequently asked questions
Unimac Pharmaceutical is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 02 August 2018 (8+ years old) and is registered under CIN U51909DL2018PTC337110.
Unimac Pharmaceutical has 2 current directors:
- Sunil Chugh - Director
- Deepak Batra - Director
The latest financial statements of Unimac Pharmaceutical on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Unimac Pharmaceutical is 07AACCU2822K1ZB, registered in Delhi.
The CIN (Corporate Identification Number) of Unimac Pharmaceutical is U51909DL2018PTC337110. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unimac Pharmaceutical has 2 court cases on record: 2 filed against it.
Unimac Pharmaceutical was incorporated on 02 August 2018, making it 8+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Unimac Pharmaceutical by revenue are Tetramed Biotek Private Limited, Sanket Pharmaceuticals Pvt Ltd, Umar Medicare Private Limited, Medtabs Pharma Private Limited, Proficon Medisol Private Limited and 1 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Deepak Batra was appointed as Director on 02 Aug 2018. Sunil Chugh was appointed as Director on 02 Aug 2018.
The registered office of Unimac Pharmaceutical is at B – 23 FF Kh.No.32111 Panjabi Basti Nangloi, New Delhi, Delhi, India – 110041.
Unimac Pharmaceutical operates in the pharma industry, in the pharmaceutical retailers and distributors segment.